BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

In terms of analyst outlook, Jefferies has maintained their Buy rating for Quest Diagnostics and raised their price target to $190, reflecting confidence in the company's growth prospects. The ...

Bank of America upped their price target on shares of Quest Diagnostics from $179.00 to $182.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. UBS Group lifted ...

Quest Diagnostics price target raised to $198 from $190 at BofA BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on ...

Grail shares are trading higher Wednesday after the company announced a new collaboration with Quest Diagnostics aimed at improving provider access to its Galleri multi-cancer early detection test.

During the last three months, 9 analysts shared their evaluations of Quest Diagnostics DGX, revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their ...

This was the stock's second consecutive day of losses.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...